JUNS
JupiterยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About JUNS
Jupiter Neurosciences, Inc.
A clinical stage drug platform company specializing in the treatment of neuroinflammation
1001 North US HWY 1, Suite 504, Jupiter, Florida 33477
--
Jupiter Neurosciences, Inc., was incorporated in Delaware in January 2016. The company is a clinical stage research and development pharmaceutical company. The company has developed a unique resveratrol platform product for the treatment of neuroinflammation. The product, called JOTROL, has a number of potential indications for rare diseases, primarily for mucopolysaccharidosis type 1, Friedreich's ataxia and MELAS, as well as ALS in early development. The company will be highly focused on the expected positive impact of JOTROL on neuroinflammation in all indications they are seeking. Based on the available scientific literature, they believe that JOTROL is the first and only resveratrol product in the world that provides a therapeutic effective dose of resveratrol in the blood without causing gastrointestinal (GI) side effects.
Company Financials
EPS
JUNS has released its 2025 Q3 earnings. EPS was reported at -0.07, versus the expected -0.08, beating expectations. The chart below visualizes how JUNS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
